PL439315A1 - The method of determining the risk of cancer in women depending on the concentration of selenium in the blood - Google Patents

The method of determining the risk of cancer in women depending on the concentration of selenium in the blood

Info

Publication number
PL439315A1
PL439315A1 PL439315A PL43931518A PL439315A1 PL 439315 A1 PL439315 A1 PL 439315A1 PL 439315 A PL439315 A PL 439315A PL 43931518 A PL43931518 A PL 43931518A PL 439315 A1 PL439315 A1 PL 439315A1
Authority
PL
Poland
Prior art keywords
selenium
concentration
cancer
blood
risk
Prior art date
Application number
PL439315A
Other languages
Polish (pl)
Other versions
PL248410B1 (en
Inventor
Jan LUBIŃSKI
Anna Jakubowska
Wojciech MARCINIAK
Magdalena MUSZYŃSKA
Róża Derkacz
Katarzyna Kaczmarek
Tomasz Huzarski
Jacek Gronwald
Cezary Cybulski
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL439315A priority Critical patent/PL248410B1/en
Publication of PL439315A1 publication Critical patent/PL439315A1/en
Publication of PL248410B1 publication Critical patent/PL248410B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka raka, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia selenu w próbce biologicznej osoby badanej, przy czym stężenie selenu wskazuje na znacząco obniżone ryzyko: rozwoju raka pozasutkowego w przypadku optymalnych stężeń selenu we krwi, zwłaszcza w przedziale od 98 µg/l do 108 µg/l; rozwoju raka, zwłaszcza pozasutkowego, w przypadku występowania stężenia selenu we krwi, zwłaszcza leżącego w przedziale od 98 µg/l do 108 µg/, przy jednoczesnym występowaniu niskiego stężenia arsenu, szczególnie poniżej 1,10 µg/l.The subject of the application is a method of determining the risk of cancer, characterized by the fact that it includes a quantitative assessment of the concentration of selenium in a biological sample of the tested person, where the concentration of selenium indicates a significantly reduced risk of: developing extramuminal carcinoma in the case of optimal concentrations of selenium in the blood, especially in the range of 98 µg / L to 108 µg / L; the development of cancer, especially extramuminal cancer, in the presence of selenium concentration in the blood, especially in the range from 98 µg / l to 108 µg /, with the simultaneous presence of low arsenic concentration, especially below 1.10 µg / l.

PL439315A 2018-05-17 2018-05-17 Method for determining the risk of cancers in women, depending on concentration of selenium in the blood PL248410B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL439315A PL248410B1 (en) 2018-05-17 2018-05-17 Method for determining the risk of cancers in women, depending on concentration of selenium in the blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL439315A PL248410B1 (en) 2018-05-17 2018-05-17 Method for determining the risk of cancers in women, depending on concentration of selenium in the blood

Publications (2)

Publication Number Publication Date
PL439315A1 true PL439315A1 (en) 2022-05-30
PL248410B1 PL248410B1 (en) 2025-12-08

Family

ID=81751205

Family Applications (1)

Application Number Title Priority Date Filing Date
PL439315A PL248410B1 (en) 2018-05-17 2018-05-17 Method for determining the risk of cancers in women, depending on concentration of selenium in the blood

Country Status (1)

Country Link
PL (1) PL248410B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL442921A1 (en) * 2022-11-23 2024-05-27 Read-Gene Spółka Akcyjna Reducing the risk of death in women with a hereditary predisposition to breast cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL442921A1 (en) * 2022-11-23 2024-05-27 Read-Gene Spółka Akcyjna Reducing the risk of death in women with a hereditary predisposition to breast cancer

Also Published As

Publication number Publication date
PL248410B1 (en) 2025-12-08

Similar Documents

Publication Publication Date Title
Garland et al. Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: A meta-analysis
MA44334A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
BR112017003419A2 (en) stable anti-il-4r-alpha antibody formulation
EA202190237A1 (en) METHODS TO REDUCE INTERFERING EFFECTS OF A DRUG TARGET IN IMMUNOLOGICAL ANALYSIS FOR DRUG ANTIBODIES (ADA)
EA202191666A1 (en) ANTIBODIES TO IL-27 AND THEIR USE
RU2016104892A (en) COMPOSITIONS AND METHODS FOR IDENTIFYING THE RISK OF DEVELOPING A CANCER DISEASE IN A SUBJECT
PL425603A1 (en) Method for determining the risk of cancers in women, who are the carriers of mutation in gene BRCA1 and BRCA2 in relation to concentration of arsenic, cadmium, zinc and/or selenium in the blood
PL437046A1 (en) Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
PL439316A1 (en) How to determine the risk of cancer in women according to the concentration of zinc in the blood
PL439313A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood
PL425602A1 (en) Method for determining the risk of cancers in women, who are not the carriers of mutation in gene BRCA1 and BRCA2 in relation to concentration of arsenic, cadmium, zinc and/or selenium in the blood
PL433150A1 (en) Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level
PL439314A1 (en) Method for determining the risk of cancers in women, depending on concentration of cadmium in the blood
PL439318A1 (en) Method of determining the risk of cancers in women depending on the concentration of selenium in the blood of women who are carriers of the most common mutations in the BRCA1 and BRCA2 genes
PL439319A1 (en) The method of determining the risk of cancer in women depending on the zinc in the blood of women who are carriers of the most common mutations in the BRCA1 and BRCA2 genes
PL439317A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations
PL440972A1 (en) Method of determining the risk of cancer in women depending on the ratio of selenium to arsenic concentrations in blood
PL437896A1 (en) Way to determine the risk of cancer in men according to the concentration of arsenic in the blood
PL417957A1 (en) Method for determining the risk of prostatic carcinoma
PL446712A1 (en) Correlation between serum selenium and zinc concentrations as a prognostic marker in patients with prostate cancer
PL437899A1 (en) Way to determine the risk of cancer in men according to the concentration of lead in the blood
PL438655A1 (en) Method of determining the risk of cancer in women depending on concentration of lead in the blood
PL437895A1 (en) Way to determine the risk of cancer in men according to the concentration of copper in the blood
BR112021017144A2 (en) Assay to detect a membrane-associated protein, methods to quantify the concentration of circulating protein, to determine whether a patient with b-cell lymphoma is likely to exhibit a response to an anti-cd20 therapy, to determine the affinity of an anti-cd20 antibody cd20, to determine the activation of t cells and method of treating a tumor